Monsanto (MON) is a one of the leading companies in the agrochemical and agricultural biotechnology sectors and is at the forefront of genetically engineered seeds. Over the years, Monsanto has become the flagship of negative publicity and sentiment in the farming community. For shareholders, however, there lies some very good news in the company's imminent future. In the wake of the Monsanto's acquisition by Bayer, shareholders will end up realizing one of two possibilities: the deal goes through and the price differential with Bayer's offer is locked in, or the deal does not go through and shareholders get a solid cash boost. The only question is – why are you not aboard this train?
FinancialsOver the past two years, revenue has decreased from a peak of $15.848 billion in 2014 to $13.502 billion in 2016. The company's fiscal second and third quarters ending in February and May 2017 have shown promise and a lot of commentary around the market suggests that the stock will outperform this year. Sales were higher 6.64% on average on a year on year basis. In the last few years, agricultural product companies and chemical companies have delved into each others product markets; hence, I believe it's appropriate to compare Monsanto with CF Industries (CF) and FMC Corporation (FMC). A Monsanto – Dow Chemical comparison has been done way too many times and at this point, it would add little value to the reader.
Top 5 Biotech Stocks To Own For 2019: ArQule Inc.(ARQL)
Advisors' Opinion:- [By Max Byerly]
Get a free copy of the Zacks research report on ArQule (ARQL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Motley Fool Transcribers]
Arqule Inc (NASDAQ:ARQL)Q4 2018 Earnings Conference CallMarch 07, 2019, 9:00 a.m. ET
Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:Operator
- [By Maxx Chatsko]
Shares of ArQule (NASDAQ:ARQL) rose over 70% today after the company reported full-year 2018 operating results and provided full-year 2019 guidance. That said, investors are probably used to wild swings in the stock price by now. The development-stage pharma didn't turn in a particularly impressive performance last year. Management expects revenue to drop significantly in the year ahead as collaboration revenue dries up, which will also widen operating losses.
- [By Joseph Griffin]
Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.
- [By Logan Wallace]
ValuEngine downgraded shares of ArQule (NASDAQ:ARQL) from a strong-buy rating to a buy rating in a research report sent to investors on Saturday.
Several other brokerages also recently issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a hold rating to a buy rating and set a $2.75 target price for the company in a research note on Tuesday, May 8th. B. Riley set a $4.00 target price on shares of ArQule and gave the company a buy rating in a research note on Monday, March 26th. Roth Capital raised their target price on shares of ArQule from $5.00 to $6.00 and gave the company a buy rating in a research note on Tuesday, April 17th. BidaskClub upgraded shares of ArQule from a hold rating to a buy rating in a research note on Saturday, May 19th. Finally, Leerink Swann upgraded shares of ArQule from a market perform rating to an outperform rating in a research note on Thursday, April 5th. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $5.35.
Top 5 Biotech Stocks To Own For 2019: Alnylam Pharmaceuticals Inc.(ALNY)
Advisors' Opinion:- [By Cory Renauer]
Staying on top of every new drugmaker takes a lot more time than you probably have. That said, Alnylam Pharmaceuticals (NASDAQ:ALNY) and Pfizer (NYSE:PFE) shareholders want to keep their eyes on young Eidos and its lead candidate. Here's why.
- [By Brian Orelli]
Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.
- [By Brian Orelli]
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) were up 19% at 12:04 p.m. EDT on Monday after rival Pfizer (NYSE:PFE) released data for its transthyretin amyloid (ATTR) drug tafamidis at the ESC Congress 2018, which were also published in the New England Journal of Medicine. Earlier this month, Alnylam got its ATTR drug, Onpattro, approved by the Food and Drug Administration. Shares of Ionis Pharmaceuticals (NASDAQ:IONS) and Akcea Therapeutics (NASDAQ:AKCA), which are jointly developing another ATTR drug, Tegsedi, are up 10% and 2.6% respectively.
- [By Cory Renauer]
Anyone who likes a good underdog story will want to keep their eye on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) and GW Pharmaceuticals PLC (NASDAQ:GWPH) through this year and next as they launch their first products in the U.S. Smaller biotechs have a terrible track record when it comes to launching new drugs on their own, but most analysts expect these companies to buck the trend and propel their recently approved drugs to blockbuster status within a few years.
- [By Stephan Byrd]
Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research note issued on Wednesday.
- [By Max Byerly]
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.
Top 5 Biotech Stocks To Own For 2019: Biogen Idec Inc(BIIB)
Advisors' Opinion:- [By Chris Lange]
Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 3.50 million shares from the previous 3.16 million. The stock recently traded at $262.15, within a 52-week range of $244.28 to $370.57.
- [By Garrett Baldwin] Shares of Ford Motor Co. (NYSE: F) were flat despite dismal news out of China. This morning, the company reported a 38% slump in Chinese sales during the month of June. It was a terrible first six months for the iconic vehicle manufacturer. The company said that its Chinese operations saw a 25% slide in sales over the first half of the year. That was the largest six-month decline since launching its Chinese operations in 2001. Shares of Tesla Inc. (Nasdaq: TSLA) are off more than 1% after California regulators announced a new probe into the company. The probe was announced following a safety complaint filed with the Occupational Safety and Health Administration. The agency has not provided any details on the case. Shares of Biogen Inc. (Nasdaq: BIIB) popped more than 14% after the company announced positive results from a trial for an Alzheimer's drug. The phase 2 study examined BAN2401, an anti-amyloid beta protofibril antibody. It was tested on 856 patients with early stages of Alzheimer's disease. In a research note, JPMorgan Chase & Co. (NYSE: JPM) announced that the results would be positive for Biogen's drug pipeline. Look for an earnings report Friday from InnerWorkings Inc. (Nasdaq: INWK). Wall Street projects that the company will report earnings per share of $0.09 on top of $284.9 million in revenue.
Follow Money Morning on Facebook, Twitter, and LinkedIn.
- [By Brian Feroldi]
Amgen (NASDAQ:AMGN) and Biogen (NASDAQ:BIIB) have a lot in common. They are both hugely successful biotech giants that were founded decades ago. They each have produced stellar returns for their long-term shareholders and crank out copious amounts of cash flow each year.
- [By Shannon Jones]
In this week's episode of Industry Focus: Healthcare, host Michael Douglass and Motley Fool contributor Shannon Jones look at what went wrong with Incyte's Epacadostat, where the company can go from here, and what this unfortunately means for the immuno-oncology sector on the whole. Then, in more pleasant news, the hosts dive into Novartis' (NYSE:NVS) newest acquisition of gene therapy company AveXis. Find out what this means for Novartis, why Biogen (NASDAQ:BIIB) might be getting the stink eye from their investors right about now, whether or not Novartis overpaid to tuck this company under their belt, and more.
- [By Chris Lange]
Short interest in Biogen Inc. (NASDAQ: BIIB) decreased slightly to 3.09 million shares from the previous 3.15 million. The stock recently traded at $344.57, within a 52-week range of $249.17 to $388.67.
- [By Chris Lange]
Short interest in Biogen Inc. (NASDAQ: BIIB) decreased to 3.45 million shares from the previous 3.50 million. The stock recently traded at $274.50, within a 52-week range of $244.28 to $370.57.
Top 5 Biotech Stocks To Own For 2019: Amgen Inc.(AMGN)
Advisors' Opinion:- [By Max Byerly]
Hammer Asset Management LLC purchased a new stake in Amgen, Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent 13F filing with the SEC. The firm purchased 16,988 shares of the medical research company’s stock, valued at approximately $3,136,000. Amgen makes up 2.7% of Hammer Asset Management LLC’s holdings, making the stock its 13th largest holding.
- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.58 million shares from the previous level of 10.61 million. Shares were last seen trading at $193.15, in a 52-week trading range of $163.31 to $201.23.
- [By Stephan Byrd]
PNC Financial Services Group Inc. trimmed its stake in Amgen, Inc. (NASDAQ:AMGN) by 0.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 2,120,853 shares of the medical research company’s stock after selling 6,484 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Amgen were worth $391,489,000 as of its most recent SEC filing.
- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) is expected to release its most recent quarterly results on Thursday. The consensus forecast calls for $3.54 in EPS and $5.74 billion in revenue for the second quarter. Shares traded on Friday's close at $190.60. The consensus price target is $196.10, and the 52-week range is $163.31 to $201.23.
No comments:
Post a Comment